Lilly Global Health Partnership - Expanding Global Access to Healthcare

Partnership objectives

1) Address gaps in care for cancer, diabetes and tuberculosis.

2) Improve access to care for 30 million people in resource limited settings each year by 2030.

Global Access to Healthcare Global Access to Healthcare Copyright Eli Lilly

What are the health needs and challenges?

In many parts of the world there exists a lack of timely diagnosis and access to quality care. This new five-year, $90 million investment in the Lilly Global Health Partnership will improve access to treatment for diabetes, cancer and tuberculosis (TB) and contribute to a company-wide effort to  reach 30 million people annually by 2030 (known as the Lilly 30x30). The expanded Lilly Global Health Partnership builds on and accelerates ongoing work of the Lilly MDR-TB and NCD Partnerships that have been running since 2003 and 2011 respectively. 

Description of partnership activities and how they address needs and challenges

Working with expert partners, the Lilly Global Health Partnership helps people living in communities with limited resources in Brazil, China, India, Kenya, Mexico, Russia, South Africa and the U.S. Lilly is advancing its existing global health work in many of these communities while identifying new opportunities for partnership. Consistent with the company's evidence-based approach (known as Research-Report-Advocate), the Lilly Global Health Partnership researches new models of care, reports findings and advocates for the scale-up of the most effective solutions to help more people. 

The Lilly Global Health Partnership also includes a new $15 million commitment to the Infectious Disease Research Institute (IDRI). This will extend an eight-year collaboration to accelerate early-stage drug discovery and preclinical development for potential new TB medicines.

The Lilly Global Health Partnership and Lilly 30x30 extend and accelerate work done through major global health programs supported by Lilly and the Lilly Foundation over the past two decades. These include the Lilly MDR-TB Partnership, which included a decade-long transfer of manufacturing technology for TB medicines, support of early-stage TB drug discovery and improved care in high-burden countries. In 2011, the Lilly NCD Partnership was launched to help governments and key stakeholders improve diabetes prevention and care for people in need. The Lilly Global Health Partnership encompasses and expands these continuing efforts under a single heading.  

In addition, Lilly works to improve global health through many other collaborative efforts, including ongoing product donations and funding for Academic Model Providing Access to Healthcare (AMPATH) in Kenya; support of the International Diabetes Federation's Life for a Child program; and hunger relief efforts. 

In order to reach 30 million people each year by 2030, Lilly will explore new approaches – in addition to the Lilly Global Health Partnership - within different areas of the business, including: 

  • Drug discovery for diseases disproportionately affecting people in resource-limited settings;
  • Product delivery and packaging more appropriate for people in resource-limited settings;
  • Innovative business models, alternative product pricing and patient financial assistance to improve access to care;
  • Initiatives to strengthen health systems and local treatment capacity in communities with significant gaps in care; and
  • New patient education programs.   



Lilly Global Health: Past, Present and Future

Ampath and Lilly partnership

Partnership information

Company(ies) Eli Lilly and Company

Partner(s) Abbott, Academia Sinica, Academic Model Providing Access to Healthcare (AMPATH), Addis Ababa University, Aeras Global TB Vaccine Foundation, Bill and Melinda Gates Foundation, Carlos Slim Health Institute, Cebu Leprosy and Tuberculosis Research Foundation, Center for Disease Control and Prevention (CDC), Chembio Diagnostics Systems, Donald Woods Foundation, European Vaccine Initiative, Fundação Oswaldo Cruz (Fiocruz), Gennova Biopharmaceuticals, Infectious Disease Research Institute (IDRI), Institute of Human Virology, Instituto da Criança Com Diabetes, International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), International Diabetes Federation (IDF), Massachusetts Institute of Technology, McGill University, PATH Malaria Vaccine Initiative (MVI), Population Services International (PSI), Project HOPE, Public Health Foundation of India, Sabin Vaccine Institute, Seattle Biomedical Research Institute, South African Tuberculosis Vaccine Initiative, Texas A&M University, Tokyo University, UK HIV Vaccine Consortium, Universidade Federal do Rio Grande do Sul, University of Delhi, University of Washington, US Agency for International Development (USAID), US National Institutes of Health (NIH), Walter and Eliza Hall Institute of Medical Research, Walter Reed Army Institute of Research, Weill Medical College, Cornell University

Type of Partner(s) Academia / Hospitals, Government, Multilaterals, NGOs, Other Business, PDPs, Professional Associations

Therapeutic Focus Infectious Diseases, Non-Communicable Diseases

Disease(s) Cancer, Diabetes, Tuberculosis

Program Type(s) Availability of Treatment - NCDs Access Programs, Availability of Treatment - Patient Safety & Medicines Quality, Availability of Treatment - Product Donations, Availability of Treatment - Technology Transfer - Manufacturing and Entrepreneurial Know-How, Health System Infrastructure - Health Economics and Outcomes Research, Health System Infrastructure - mHealth, Health System Infrastructure - Outreach & Medical Services, Health System Infrastructure - Training, Prevention Programs - Awareness & Outreach, Research & Development - Development of Treatments

Region(s) East Asia & Pacific, Europe & Central Asia, Latin America & Caribbean, North America, South Asia, Sub-Saharan Africa

Number of Countries 7

Country(ies) Brazil, China, India, Mexico, Russia, South Africa, United States of America

Start Date 2016

Anticipated completion date Ongoing